BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 17674979)

  • 21. Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.
    Law A; Kennedy T; Pellitteri P; Wood C; Christie D; Yumen O
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1361-8. PubMed ID: 17869022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of amifostine in the treatment of head and neck cancer with cisplatin-radiotherapy.
    Marcu LG
    Eur J Cancer Care (Engl); 2009 Mar; 18(2):116-23. PubMed ID: 19267726
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intensity-modulated radiotherapy reduces radiation-induced morbidity and improves health-related quality of life: results of a nonrandomized prospective study using a standardized follow-up program.
    Vergeer MR; Doornaert PA; Rietveld DH; Leemans CR; Slotman BJ; Langendijk JA
    Int J Radiat Oncol Biol Phys; 2009 May; 74(1):1-8. PubMed ID: 19111400
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hyperfractionated accelerated radiotherapy versus conventional fractionation both combined with chemotherapy in patients with locally advanced head and neck carcinomas: a retrospective analysis of a monoinstitutional series.
    Welz H; Pöttgen C; Abu Jawad J; Wierlemann A; Wittig A; Stüben G; Budach V; Lehnerdt G; Jahnke K; Sack H; Stuschke M
    Oncology; 2009; 76(6):405-12. PubMed ID: 19407473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. From conventionally fractionated radiation therapy to hyperfractionated radiation therapy alone and with concurrent chemotherapy in patients with early-stage nonsmall cell lung cancer.
    Jeremić B; Milicić B
    Cancer; 2008 Feb; 112(4):876-84. PubMed ID: 18172901
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alternating chemotherapy and radiotherapy in locally advanced head and neck cancer: an alternative?
    Merlano M
    Oncologist; 2006 Feb; 11(2):146-51. PubMed ID: 16476835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current and emerging standards of concomitant chemoradiotherapy.
    Adelstein DJ; Rodriguez CP
    Semin Oncol; 2008 Jun; 35(3):211-20. PubMed ID: 18544436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant chemotherapy followed by concurrent hyperfractionated radiation therapy and sensitizing chemotherapy for locally advanced (T3-T4) oropharyngeal squamous cell carcinoma.
    Finnegan V; Parsons JT; Greene BD; Sharma V
    Head Neck; 2009 Feb; 31(2):167-74. PubMed ID: 18853443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radiation-induced volume changes in parotid and submandibular glands in patients with head and neck cancer receiving postoperative radiotherapy: a longitudinal study.
    Wang ZH; Yan C; Zhang ZY; Zhang CP; Hu HS; Kirwan J; Mendenhall WM
    Laryngoscope; 2009 Oct; 119(10):1966-74. PubMed ID: 19688858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic effect of recombinant human epidermal growth factor (RhEGF) on mucositis in patients undergoing radiotherapy, with or without chemotherapy, for head and neck cancer: a double-blind placebo-controlled prospective phase 2 multi-institutional clinical trial.
    Wu HG; Song SY; Kim YS; Oh YT; Lee CG; Keum KC; Ahn YC; Lee SW
    Cancer; 2009 Aug; 115(16):3699-708. PubMed ID: 19514089
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.
    Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB
    Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Five year results of a randomized trial comparing hyperfractionated to conventional radiotherapy over four weeks in locally advanced head and neck cancer.
    Cummings B; Keane T; Pintilie M; Warde P; Waldron J; Payne D; Liu FF; Bissett R; McLean M; Gullane P; O'Sullivan B
    Radiother Oncol; 2007 Oct; 85(1):7-16. PubMed ID: 17920715
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Radical radiotherapy for invasive bladder cancer: What dose and fractionation schedule to choose?
    Pos FJ; Hart G; Schneider C; Sminia P
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1168-73. PubMed ID: 16376486
    [TBL] [Abstract][Full Text] [Related]  

  • 34. concomitant chemoradiotherapy with mitomycin C and cisplatin in advanced unresectable carcinoma of the head and neck: phase I-II clinical study.
    Strojan P; Karner K; Smid L; Soba E; Fajdiga I; Jancar B; Anicin A; Budihna M; Zakotnik B
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):365-72. PubMed ID: 18394816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IMRT dose fractionation for head and neck cancer: variation in current approaches will make standardisation difficult.
    Ho KF; Fowler JF; Sykes AJ; Yap BK; Lee LW; Slevin NJ
    Acta Oncol; 2009; 48(3):431-9. PubMed ID: 18781445
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction chemotherapy followed by concurrent chemoradiotherapy in advanced head and neck squamous cell carcinoma.
    Barone C; Grillo R; Dongiovanni D; Birocco N; Rampino M; Redda MG; Garibaldi E; Munoz F; Pecorari G; Cavalot A; Garzinodemo P; Buffoni L; Ciuffreda L; Ricardi U; Cortesina G; Giordano C; Fasolis M; Berrone S; Bertetto O; Schena M
    Anticancer Res; 2008; 28(2B):1285-91. PubMed ID: 18505067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New options in the treatment of locally advanced head and neck cancer: role for induction chemotherapy.
    Cruz JJ; Ocaña A; Navarro M; Barco ED; Fonseca E
    Cancer Treat Rev; 2008 May; 34(3):268-74. PubMed ID: 18194842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concomitant boost radiotherapy compared with conventional radiotherapy in squamous cell carcinoma of the head and neck--a phase III trial from a single institution in India.
    Ghoshal S; Goda JS; Mallick I; Kehwar TS; Sharma SC
    Clin Oncol (R Coll Radiol); 2008 Apr; 20(3):212-20. PubMed ID: 18343310
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors associated with long-term dysphagia after definitive radiotherapy for locally advanced head-and-neck cancer.
    Caudell JJ; Schaner PE; Meredith RF; Locher JL; Nabell LM; Carroll WR; Magnuson JS; Spencer SA; Bonner JA
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):410-5. PubMed ID: 18635320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction chemotherapy: to use or not to use? That is the question.
    Brizel DM; Vokes EE
    Semin Radiat Oncol; 2009 Jan; 19(1):11-6. PubMed ID: 19028340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.